Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/178486| Title: | Significant Clinical Activity of Olaparib in a Somatic BRCA1-Mutated Triple-Negative Breast Cancer With Brain Metastasis |
| Author: | Pascual, Tomás González Farré, Blanca Teixidó, Cristina Oleaga Zufiría, Laura Oses, Gabriela Ganau, Sergi Chic Ruché, Núria Riu Viladoms, Gisela Adamo, Barbara Galván, Patricia Vidal Losada, Maria Jesús Soy Muner, Dolors Urbano Ispizua, Álvaro Muñoz Mateu, Montserrat Prat Aparicio, Aleix |
| Keywords: | Càncer de mama Receptors d'hormones Expressió gènica Breast cancer Hormone receptors Gene expression |
| Issue Date: | 7-Jun-2019 |
| Publisher: | American Society of Clinical Oncology |
| Abstract: | Breast cancer is a biologically and clinically heterogeneous disease, and patients with similar clinical stage have markedly different outcomes. Triple-negative breast cancer (TNBC) is defined by the lack of expression of estrogen receptor (ER), progesterone receptor, and human epidermal growth factor receptor 2 (HER2).1,2 This subtype represents 15% to 20% of all breast cancers and is associated with the worst outcome of all subtypes, with greater tendency to distant recurrence in general and visceral metastasis in particular, including brain metastasis.3,4 To date, chemotherapy remains the standard of care for TNBC |
| Note: | Reproducció del document publicat a: https://doi.org/10.1200/PO.19.00012 |
| It is part of: | Journal of Clinical Oncology, 2019 |
| URI: | http://hdl.handle.net/2445/178486 |
| Related resource: | https://doi.org/10.1200/PO.19.00012 |
| ISSN: | 0732-183X |
| Appears in Collections: | Articles publicats en revistes (Farmacologia, Toxicologia i Química Terapèutica) Articles publicats en revistes (Medicina) |
Files in This Item:
| File | Description | Size | Format | |
|---|---|---|---|---|
| 698028.pdf | 1.28 MB | Adobe PDF | View/Open |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.